Wolverine blend
Wolverine (BPC-157 + TB-500)
Written by Aaron CuhaReviewed Sep 2026
Also known as: Wolverine stack, Wolverine peptide blend, BPC-157 / TB-500 stack
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Wolverine is two healing peptides mixed in one vial, usually 10 mg of each. It is sold for injuries. No study has ever tested the two together. And one of the two is not the molecule the label says it is.
What people take it for
- Getting back faster from a tendon, shoulder or muscle injury.
- Knee and joint pain.
- Gut problems, which is what one half of the blend is best known for.
- Training through nagging injuries instead of resting them.
What the trials actually showed
Nothing has tested the blend. Not in people, not in animals. So you are left with the two parts. For BPC-157, a 2025 review went through 544 papers and kept 36. Thirty five of those were animal or lab work. One was in people, and it was a look back at 12 patients with knee pain, where 7 said they felt better past 6 months. No control group. The reviewers wrote that no human safety data was found at all. The FDA counted five human studies of it, fewer than 110 people in total, none by a shot under the skin and none longer than two weeks. The other half is a bigger problem. TB-500 is sold as thymosin beta 4, a protein with real wound healing research. A drug testing lab put the product through a mass spectrometer. What came out was a 7 amino acid piece of that protein, not the protein. The full thing is 43 amino acids. The FDA reached the same answer on its own, and added that it found no study giving TB-500 to a human by any route. Two proper trials are now running, one with 120 people for BPC-157 in hamstring tears and one with 80 people for the TB-500 piece. Each tests one peptide on its own. Neither tests the blend. Last, the math on the vial. Mix 20 mg of powder with 2 mL of water and every unit on an insulin syringe carries 50 micrograms of each. Draw 5 units to get 250 micrograms of BPC-157 and you get 250 micrograms of TB-500 too, whether you wanted that or not. Neither peptide has a settled human dose, so the one to one split is a packing choice, not a finding.
What people report
Reports, not trial results
The good
- Faster feeling recovery from tendon and shoulder injuries, reported often.
- Less joint pain and less gut discomfort, usually credited to the BPC-157 half.
- People like that it is one shot instead of two.
The bad
- Red, sore lumps at the injection site.
- Lightheadedness right after a shot.
- You cannot change one dose without changing the other, because they share a vial. You cannot stop one either.
- If something helps or something goes wrong, both are equally to blame and you have no way to tell them apart.
- Nobody knows what is in it. The FDA looked at BPC-157 in 2026 and found mislabelled products on the market and no adequate human data.
- Both are banned in sport, so a tested athlete taking this will fail.
Where these come from: All of the good and bad above comes from peptide forums, vendor testimonial pages and clinic write ups. There are no trial exit interviews, because no trial of this blend has ever been run. The labelling and contents findings are published lab work and the FDA's own 2026 reviews, both cited on this page.
My bottom line
Here is the part that gets people. Injuries heal on their own, so whatever you took during the healing gets the credit. A 2026 review in a sports medicine journal made that exact point about these peptides. Two real trials are finally running, and I would wait for them.
An opinion, not a finding. I am a coach, not a doctor.
Overview
Two gray-market healing peptides in one vial, usually 10 mg of each, sold for injury recovery. No study has ever tested the combination. BPC-157's systematic review found 36 studies of which 35 were preclinical, and what vendors sell as TB-500 is not thymosin beta 4 but a seven amino acid fragment of it.
Wolverine is the most recognisable name in gray-market recovery peptides. The standard preparation is 10 milligrams of BPC-157 with 10 milligrams of TB-500 in a single vial, marketed on the idea that the two healing pathways add up.
No trial has tested them together. Not in people, not in animals. Everything written about the blend is assembled from the separate literatures of its two components, and both of those have problems worth knowing before you assemble anything.
BPC-157 is a pentadecapeptide with a substantial animal record, mostly from one research group in Zagreb. A 2025 systematic review from an orthopaedic sports medicine perspective screened 544 articles from 1993 to 2024 and included 36 studies: 35 preclinical and 1 clinical. That single clinical item was a retrospective look at intra-articular injection for unspecified chronic knee pain in which 7 of 12 patients reported relief beyond 6 months. The reviewers state plainly that no clinical safety data was found.
TB-500 has a different problem, and it is about identity. TB-500 is routinely described as thymosin beta 4. It is not. When a doping control laboratory analysed the TB-500 formulation by high resolution mass spectrometry, what it identified was Ac-LKKTETQ, the N-terminal acetylated 17 to 23 fragment of human thymosin beta 4. That is seven amino acids out of 43. So the large Nature and wound-healing literature on thymosin beta 4 is literature about a different molecule from the one in the vial.
Now the arithmetic of the vial, which is simpler here than on the copper blends and still worth doing. A standard Wolverine vial is 10 milligrams of each peptide, so 20 milligrams of powder that is 50% BPC-157 and 50% TB-500. Reconstitute it in 2 mL of bacteriostatic water and it holds 10 mg/mL, which is 100 micrograms of powder on every unit mark of a 100 unit insulin syringe: 50 micrograms of BPC-157 and 50 micrograms of TB-500. Draw to 250 micrograms of BPC-157 and you are at 5 units, and those 5 units deliver exactly 250 micrograms of TB-500 as well, whether or not that is a TB-500 dose you would have chosen. One to one is a packaging decision. Neither component has an established human dose, so there is nothing for the ratio to be correct against.
That fixed ratio is the specific risk of buying any blend, and it is worth stating plainly once. You cannot titrate one component, because the plunger moves both. You cannot stop one when a side effect appears, because stopping means stopping both. And you cannot attribute a benefit or a harm to either ingredient, because you took them on the same day, from the same syringe, at a ratio you did not set. Two separate vials cost more and are the only version of this that can be adjusted or stopped one part at a time.
As of this review date there are registered single-agent trials for each component, and none for the pair.
Mechanism of action
Assumed additive, and assumed is the operative word. BPC-157 is reported in preclinical models to raise growth hormone receptor expression and several pathways involved in cell growth and angiogenesis while reducing inflammatory cytokines. The thymosin beta 4 parent protein sequesters G-actin and promotes cell migration, and the Ac-LKKTETQ fragment that TB-500 actually contains sits within the actin-binding region. No paper describes what happens when the two are given together, whether their effects are additive, redundant or interfering, or whether the two peptides are stable in one vial.
Human evidence
None for the combination. For the components, one retrospective case series and two single-agent trials that are still recruiting.
- Zero studies of BPC-157 with TB-500 together, in any species.
- FDA found no study administering TB-500 to humans by any route, no human pharmacokinetic data and no FAERS reports through March 26, 2025, in its 2026 evaluation of the substance.
- BPC-157 systematic review: 36 included studies, 35 preclinical, 1 clinical. The clinical item is retrospective, 7 of 12 patients reporting relief beyond 6 months after an intra-articular knee injection.
- NCT07437547, BPC 157 for acute hamstring strain, phase 2, estimated 120 participants, recruiting, placebo-controlled, single agent.
- NCT07487363, TB-500 described as the thymosin beta 4 17 to 23 fragment, phase 1 or 2, estimated 80 participants, recruiting, placebo-controlled, cardiovascular biomarkers in stable atherosclerotic disease, single agent.
- FDA staff reviewing BPC-157 ahead of the July 2026 compounding advisory committee found no adequate human data and mislabelled products in the market.
What this does not tell you: A blend cannot inherit the evidence of its parts, and here the parts do not have much to lend. The BPC-157 clinical item is a retrospective series of 12 people with unspecified knee pain and no control group. The TB-500 situation is worse than thin: the product is not the molecule its marketing names, so the wound healing and cardiac literature usually quoted for it describes something else. Nothing is known about whether the two peptides are stable together in one vial, whether their doses interact, or what a combined adverse event profile looks like.
Reading the research record
Three things make this particular blend worth a page rather than a dismissal.
The first is that both components now have registered, placebo-controlled, single-agent human trials recruiting. That is new, and it is the right way to find out. Neither trial tests the blend, so whatever they report will be about one peptide at one dose in one condition.
The second is the identity problem, which is specific and documented. TB-500 sold as thymosin beta 4 was characterised by a doping laboratory as Ac-LKKTETQ, a seven amino acid fragment. Anyone reasoning from the thymosin beta 4 literature to the contents of a Wolverine vial is making a substitution nobody has justified.
The third is the placebo point, raised in the 2026 Sports Medicine review. Injury recovery is the single domain where subjective improvement is hardest to separate from natural healing, because the tissue was going to improve anyway. A blend taken during recovery from an injury that resolves on its own will be credited with the resolution. That is not a reason the blend cannot work. It is the reason single-agent placebo-controlled trials are the only thing that will settle it.
Underneath all three of those sits the fixed ratio, which is the plainest thing wrong with any blend and the one buyers weigh least. The vendor made every dose decision in the vial before it shipped. In a 20 milligram vial reconstituted in 2 mL, each unit on the syringe is 50 micrograms of BPC-157 and 50 micrograms of TB-500, permanently locked together. You cannot titrate one. You cannot stop one when a side effect appears. And if something improves or something goes wrong, both ingredients are equally credible and nothing you can do at home will separate them. Neither peptide has an established human dose, so the one-to-one ratio is not even anchored to a number somebody defended in print. Compared with the copper blends this one at least splits the mass evenly, but even division is not the same as a justified dose.
The evidence, charted
Fig. 1 · evidence composition
1of 8 citations (13%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 5 distinct years, 1999 to 2026, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Review2025
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
544 articles from 1993 to 2024 screened, 36 included: 35 preclinical studies and 1 clinical study. The single clinical item was a retrospective report in which 7 of 12 patients reported relief beyond 6 months after intra-articular BPC-157 for unspecified chronic knee pain. BPC-157 is metabolised in the liver with a half-life under 30 minutes and cleared renally. Preclinical safety studies showed no adverse effects across several organ systems, and the reviewers state that no clinical safety data was found. They classify their own evidence base as level IV and level V.
HSS Journal - In vitro2012
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.
A doping control laboratory analysed the TB-500 formulation by high performance liquid chromatography and high resolution mass spectrometry and identified its contents as Ac-LKKTETQ, the N-terminal acetylated 17 to 23 fragment of human thymosin beta 4. Seven amino acids, not the 43 amino acid protein. This is the paper that separates TB-500 from thymosin beta 4, and it is why the thymosin beta 4 literature cannot be read across to the vial.
Drug Testing and Analysis - Animal2003
Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth.
Transected rat Achilles tendon, with tendocyte culture work alongside. One of the foundational animal results behind the tendon claims made for this blend. Rats. Single agent, no TB-500 involved.
Journal of Orthopaedic Research - Animal1999
Thymosin beta4 accelerates wound healing.
The full-length thymosin beta 4 protein accelerated wound healing in an animal model. Included deliberately: this is the kind of paper cited to sell TB-500, and the product analysed by doping control was a seven amino acid fragment rather than this protein.
Journal of Investigative Dermatology - Review2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
A 2026 narrative review covering BPC-157, thymosin beta 4 and TB-500, described in the paper as a thymosin beta-4 fragment, alongside CJC-1295, ipamorelin, GHK-Cu and others. Its summary judgement is that many unapproved peptides show favourable tissue repair outcomes in animal models, that rigorous human safety data are scarce, and that there is potential for serious harm. It also discusses the placebo effect as a mediator of perceived peptide efficacy and how social media amplifies it, which is the most relevant sentence in the literature for a blend sold on testimonials.
Sports Medicine - Human2026
BPC 157 for Acute Hamstring Muscle Strain Repair
A recruiting phase 2 trial with an estimated 120 participants comparing pentadecapeptide BPC 157 against placebo for acute hamstring strain. Single agent. It is the first properly controlled human test of BPC-157 for a musculoskeletal injury, it has not reported, and it does not involve TB-500.
ClinicalTrials.gov - Review2026
FDA briefing document on BPC-157 for the July 2026 PCAC meeting
FDA's evaluation counted five published human studies of BPC-157 totalling fewer than 110 subjects, two of them published only as meeting abstracts, with no study dosing longer than two weeks and none administering the peptide by subcutaneous injection, which is the route this blend is sold for. Staff found no adequate human data and mislabelled products in the market.
FDA - Review2026
FDA Evaluation of TB-500-Related Bulk Drug Substances (TB-500 free base and TB-500 acetate)
FDA defines TB-500 as the acetylated heptapeptide Ac-LKKTETQ, residues 17 to 23 of thymosin beta-4, molecular weight 889.01, and states that thymosin beta-4 and TB-500 are not the same substance. The agency found no study administering TB-500 to humans by any route, no human pharmacokinetic data, and no FAERS reports through March 26, 2025. The regulator reached the same conclusion as the doping laboratory, independently.
U.S. Food and Drug Administration, CDER review memorandum, 2026
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Faster-feeling return from soft tissue injuries, most often tendon and shoulder complaints, reported during periods that also included rest and rehabilitation.
- Reduced joint and gut discomfort attributed to the BPC-157 component.
- Injection site irritation and occasional lightheadedness after dosing.
- Considerable disagreement about dosing, because the blend fixes a ratio the user did not choose and neither component has an established human dose.
- Recurrent concern about product identity and purity, which the seized-material and mass spectrometry literature supports as a real risk rather than a forum rumour.
Sources: Peptide and bodybuilding forums, vendor testimonial pages and clinic write-ups. These are uncontrolled self-reports from people who were usually also resting and rehabilitating an injury, and they are recorded here as reports, not as findings.
Frequently asked questions
Is there any study of the Wolverine blend?
No. Not one study has tested BPC-157 and TB-500 together, in people or in animals. Everything written about the blend is stitched together from the separate literatures of the two components.
Is TB-500 the same as thymosin beta 4?
No, and this is the most important thing on the page. A doping control laboratory analysed the TB-500 formulation and identified it as Ac-LKKTETQ, the N-terminal acetylated 17 to 23 fragment of thymosin beta 4. Seven amino acids out of 43. The thymosin beta 4 research does not describe what is in the vial.
Does BPC-157 have human evidence?
Barely. A 2025 systematic review found 36 studies, 35 of them preclinical. The one clinical item was retrospective: 7 of 12 patients reported relief beyond 6 months after an intra-articular knee injection for unspecified chronic pain. A placebo-controlled phase 2 trial in acute hamstring strain is now recruiting and has not reported.
Why 10 mg and 10 mg?
Vendor convention, not pharmacology. Neither component has an established human dose, so a fixed one-to-one ratio in a shared vial is a packaging decision. It also means you cannot adjust one without adjusting the other.
How does Wolverine compare to KLOW and GLOW?
Same category of product, different ingredient list. KLOW adds GHK-Cu and KPV, GLOW adds GHK-Cu. None of the three has been tested as a combination, and in KLOW and GLOW the copper peptide makes up most of the vial by mass. Wolverine is the two-ingredient version.
Is it safe?
No clinical safety data exists for either component, which the BPC-157 systematic review says outright, and none at all for the pair. FDA staff reviewing BPC-157 in 2026 found no adequate human data and mislabelled products in the market. Both components are prohibited in sport.